Skip to content
CityAM
Main navigation
Sign Up
  • News
    • Latest News
    • Property
    • Media
    • Technology
    • Retail and leisure
    • Transport and infrastructure
    • Law & professional services
    • Legal Notices
    • Banking
    • Politics
    • CFA Institute Talk
  • Markets & Economics
    • Markets & Economics News
    • Economics
    • Markets
    • The Trend Micro Cybersecurity Knowledge Hub
    • Talk Crypto
    • M&A Talk
  • Crypto A.M.
    • Crypto News
    • Crypto Magazine
    • Crypto AM Summit & Awards 2022
  • Opinion
    • Features
    • Letters
    • The City View
  • Money
    • Jobs and Money News
    • Personal Development
    • Jobs
    • Fintech
    • Money
    • Personal Finance
    • Nine smart ideas for improving your financial outlook
    • Warwick Business School
  • Unwind
    • Life & Style
    • Sport
    • The Punter
    • The Magazine
    • Travel
    • Sport Business
    • The Punter Podcast
    • Culture
    • Six Nations 2023
    • LIV Golf
    • Aramco Team Series
  • Impact A.M.
    • Impact A.M.
    • DiverCity Podcast
    • Partner Hubs
  • Latest Paper
  • Jobs
  • CityAM Awards 2023
  • Charity

Pharmaceuticals

  • GSK brings in zosta lot more cash as drugs giant’s turnover boosted by shingles vaccine and HIV medicines

    Drugs giant GSK has posted better-than-forecast revenues for the first quarter thanks to strong sales of its shingles vaccine and HIV medicines. The FTSE 100 group saw earnings fall 15 per cent on a constant currency basis to £2.1bn in the first quarter as revenues dropped eight per cent to £7bn after sales of its Covid-19 treatment [...]

  • GSK coughs up £1.6bn for Bellus as pharma giant boosts its patent medicine cabinet

    DRUGS

    GSK plans to buy developer Bellus Health in an all-cash deal for £1.6bn as the drugmaker expands its bet on respiratory therapies.

  • Astrazeneca’s shares rise, as cancer drug uptake offsets fall in sales of pharma giant’s Covid-19 vaccine

    Pharma results

    Astrazeneca has posted what it claimed were “strong” financial results for the full year 2022 as surging demand for cancer medicines offset a fall in Covid vaccine revenues. Shares in Astrazeneca jumped on the news as the firm said it expects another year of double-digit revenue growth in 2023. The British firm’s strong results came [...]

  • Warning of Lemsip, cough and cold medicine shortage as Brits battle winter flu

    January 4, 2023

     Brits are struggling to get hold of cough and cold medicine as a nasty strain of flu sweeps the nation.  It has been reported that there is a shortage of medicines such as throat lozenges, cough mixtures, Lemsip powders and pain killers. This comes after the UK Health and Security Agency issued a warning about [...]

  • Eyes peeled: Five technologies to watch next year

    December 27, 2022

    The year of the Great Tech Sell-Off is coming to a close. But in this Digital Age, technology is only going to get more exciting, useful, and ethically questionable – so here’s five technologies to watch out for next year. SOLAR Solar power is becoming cheaper, more efficient and increasingly attractive for Brits looking to [...]

  • Drug developer files patents for cancer treatment which ‘outperforms’ AstraZeneca offering

    December 20, 2022

    Drug development company Nuformix has reformulated and improved one of AstraZeneca’s top cancer drugs, piquing investor interest today. Shares in the London-listed firm jumped nearly a quarter to 35p per share by early afternoon on Tuesday. Nuformix, which focuses on fibrosis and cancer drug repurposing, announced that the drug, known as Olaparib, had “outperformed” AstraZeneca’s [...]

  • European regulator injects hope into AstraZeneca’s bid to tackle cancer

    December 19, 2022

    The European Medicines Agency has handed AstraZeneca a number of recommendations and one approval for a trio of cancer drugs the Big Pharma firm is looking to market in the continent. AstraZeneca’s cancer drug Enhertu has been given the green light by the European regulator for use among patients with gastric cancer. Around 136,000 cases [...]

  • Drug developer C4X shares fly after signing £330m AstraZeneca licensing deal

    November 28, 2022

    Drug developer C4X Discovery has signed an exclusive licensing agreement worth up to $402m (£334m) with pharma giant AstraZeneca to develop oral therapy to treat inflammatory diseases. London-listed C4XD’s shares have rocketed this morning, up nearly 40 per cent to 28.5p so far. As part of the deal, C4XD will receive pre-clinical milestone payments worth up [...]

  • Merck inks £1.1bn deal for cancer drug developer Imago

    November 21, 2022

    American pharmaceutical giant Merck has today inked a $1.35bn (£1.14bn) deal for cancer drug developer Imago BioSciences. The offer of $36 (£30.4bn) a share represents a nearly 107 per cent premium on the company’s last closing price. The deal is intended to bolster Merck’s portfolio of blood disorder treatments, with onlookers expecting the company’s blockbuster [...]

  • Getting The Care You Need

    November 17, 2022  |  Sponsored

    Seeking help for your health concern in the right place within the NHS is critical to ensuring you receive the appropriate care at the right time. Practical support and resources are accessible via .nhs.uk to help you find the right first step towards getting the care you need. The online service offers A-Z guides on [...]

Posts navigation

  • Page 1
  • Page 2
  • Page 3
  • …
  • Page 12
  • Next

Trending Articles

  • Bank of England to surpass Federal Reserve and hike interest rates to 15-year high

  • Revealed: KPMG slashes UK bonuses as dealmaking drought hits fees

  • Record £9bn pumped into ISAs as Brits capitalise on higher interest rates

  • Interest rate hikes triggers house price fall and analysts think there's further to go

Subscribe

Subscribe to the City A.M. newsletter to have our top stories delivered directly to your inbox.

Subscribe
  • About us
  • Advertising
  • Contact
  • Terms & Conditions
  • Privacy Policy
  • News
  • Markets & Economics
  • Opinion
  • Jobs and Money
  • Unwind
  • Crypto A.M.
  • The Punter
  • COP 26
  • Awards 2023

Follow us for breaking news and latest updates

  • Newsletters
  • Latest paper
  • Advertising
  • CryptoAM.io
  • Awards
  • About
  • Tickets
Copyright 2023 City A.M. Limited